Stephan A Grupp Selected Research

Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome)

1/2022	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
3/2014	Managing cytokine release syndrome associated with novel T cell-engaging therapies.
2/2014	Toxicity management for patients receiving novel T-cell engaging therapies.
6/2013	Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephan A Grupp Research Topics

Disease

70	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2024 - 08/2002
61	Neoplasms (Cancer) 05/2024 - 03/2004
31	Leukemia 04/2024 - 01/2003
26	Cytokine Release Syndrome 01/2022 - 04/2013
20	Neuroblastoma 08/2023 - 03/2004
18	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 12/2011
10	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2024 - 12/2009
9	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2021 - 08/2011
8	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 05/2023 - 03/2016
8	Lymphoma (Lymphomas) 05/2021 - 12/2003
7	Residual Neoplasm 02/2024 - 09/2009
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2024 - 02/2010
5	Autoimmune Lymphoproliferative Syndrome 01/2016 - 09/2006
4	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022 - 06/2013
4	Infections 01/2021 - 03/2015
3	Critical Illness (Critically Ill) 10/2020 - 01/2016
3	Hodgkin Disease (Hodgkin's Disease) 01/2018 - 02/2010
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 10/2012
3	Splenomegaly 01/2016 - 02/2006
3	Cytopenia 01/2016 - 03/2010
3	Lymphadenopathy 01/2016 - 09/2006
3	Macrophage Activation Syndrome 09/2014 - 02/2014
3	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell) 09/2009 - 08/2002
2	B-Cell Lymphoma (Lymphoma, B Cell) 07/2023 - 01/2017
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2022 - 01/2018
2	Synovial Sarcoma (Synovioma) 01/2022 - 10/2019
2	cell-associated neurotoxicity 01/2022 - 12/2020
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021 - 01/2018
2	Fever (Fevers) 10/2021 - 02/2017
2	Hemorrhage 01/2021 - 03/2016
2	Hypersensitivity (Allergy) 11/2020 - 09/2010
2	COVID-19 11/2020 - 01/2020
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2018 - 06/2009
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2018 - 06/2009
2	Multiple Myeloma 01/2018 - 01/2018
2	Hyperferritinemia 02/2017 - 06/2013
2	Pneumonia (Pneumonitis) 01/2015 - 01/2013
2	Body Weight (Weight, Body) 10/2014 - 04/2013
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2012 - 06/2009
2	Bronchiolitis Obliterans Syndrome 01/2012 - 12/2011
1	Rare Diseases (Rare Disease) 05/2024
1	Fibrosis (Cirrhosis) 12/2023

Drug/Important Bio-Agent (IBA)

64	Chimeric Antigen ReceptorsIBA 04/2024 - 08/2011
29	tisagenlecleucelIBA 02/2024 - 04/2013
15	AntigensIBA 04/2024 - 08/2009
15	CytokinesIBA 01/2022 - 01/2008
10	Sirolimus (Rapamycin)FDA Link 01/2016 - 01/2003
9	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2016
9	tocilizumab (atlizumab)FDA Link 01/2022 - 04/2013
8	defibrotideIBA 05/2023 - 03/2016
7	Monoclonal AntibodiesIBA 01/2018 - 09/2010
6	Proteins (Proteins, Gene)FDA Link 11/2023 - 12/2006
6	Interleukin-6 (Interleukin 6)IBA 01/2022 - 02/2014
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 08/2011
6	RNA (Ribonucleic Acid)IBA 01/2018 - 03/2004
5	Surface Antigens (Surface Antigen)IBA 10/2018 - 01/2012
4	CD19 AntigensIBA 10/2023 - 12/2014
4	blinatumomabIBA 01/2022 - 06/2013
4	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 03/2010
4	AntibodiesIBA 01/2016 - 01/2008
4	TOR Serine-Threonine KinasesIBA 10/2012 - 12/2003
4	MTOR InhibitorsIBA 10/2012 - 10/2007
3	Neoplasm Antigens (Tumor Antigens)IBA 04/2024 - 03/2004
3	Messenger RNA (mRNA)IBA 01/2021 - 12/2011
3	Phosphotransferases (Kinase)IBA 12/2017 - 08/2012
2	VaccinesIBA 04/2024 - 03/2004
2	3-Iodobenzylguanidine (Iobenguane)IBA 08/2023 - 09/2013
2	siltuximabIBA 01/2022 - 01/2016
2	Interleukin-10 (Interleukin 10)IBA 11/2020 - 01/2017
2	Death Domain ReceptorsIBA 01/2020 - 12/2010
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2008
2	CD19-specific chimeric antigen receptorIBA 01/2020 - 01/2016
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2018 - 08/2002
2	Bispecific AntibodiesIBA 07/2014 - 02/2014
2	Interleukin-2 (IL2)IBA 05/2014 - 09/2010
2	InterleukinsIBA 03/2014 - 02/2014
2	InterferonsIBA 03/2014 - 02/2014
2	Isotretinoin (Accutane)FDA LinkGeneric 09/2013 - 09/2010
2	Etanercept (Enbrel)FDA Link 04/2013 - 01/2013
2	Tacrolimus (Prograf)FDA LinkGeneric 04/2013 - 12/2009
2	temsirolimus FDA Link 07/2011 - 02/2006
2	Methotrexate (Mexate)FDA LinkGeneric 12/2009 - 09/2008
2	SurvivinIBA 12/2006 - 03/2004
2	SteroidsIBA 01/2003 - 08/2002
1	Antigen Receptors (Antigen Receptor)IBA 05/2024
1	Reticulin (Reticular Fiber)IBA 12/2023
1	Transcription Factors (Transcription Factor)IBA 12/2023

Therapy/Procedure

70	Therapeutics 05/2024 - 08/2002
27	Immunotherapy 04/2024 - 03/2004
13	Drug Therapy (Chemotherapy) 08/2023 - 12/2012
12	Hematopoietic Stem Cell Transplantation 01/2019 - 02/2010
9	Cell Transplantation 03/2024 - 12/2009
9	Stem Cell Transplantation 05/2023 - 09/2009
8	Transplantation 08/2023 - 06/2006
6	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021 - 02/2010
4	Induction Chemotherapy 01/2020 - 11/2012
2	Radiotherapy 01/2020 - 09/2013
2	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 01/2020 - 09/2013
1	Secondary Prevention 02/2024
1	Aftercare (After-Treatment) 02/2024